4.1 Review

Current cellular innate immune hurdles in pig-to-primate xenotransplantation

期刊

CURRENT OPINION IN ORGAN TRANSPLANTATION
卷 13, 期 2, 页码 171-177

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOT.0b013e3282f88a30

关键词

endothelial cells; innate immune system; monocytes/macrophages; natural killer cells; neutrophils; xenograft rejection

向作者/读者索取更多资源

Purpose of review The generation of pigs lacking Gal alpha 1,3Gal (alpha Gal) or overexpressing human regulators of complement has largely overcome the barrier of hyperacute xenograft rejection. Nevertheless, delayed xenograft rejection remains a major hurdle, including humoral responses against non alpha Gal epitopes, and cellular innate immune responses. This review addresses the early interactions between the porcine endothelium and human natural killer cells, neutrophils, and monocytes/macrophages. Recent findings Whether human leukocyte recruitment to, and lysis of, porcine endothelial cells includes direct recognition of alpha Gal remains a matter of debate. Although the human natural killer receptor natural killerRP1A may directly recognize alpha Gal, several studies did not reveal significant differences regarding adhesion, transmigration, and cytotoxicity using porcine endothelial cells expressing or lacking aGal. The strong human monocyte response against pig cells partly relies on the inability of porcine ligands to ligate inhibitory human receptors, such as SIRP(x. Strategies to overcome cellular innate immune responses include transgenic expression in porcine cells of human ligands for inhibitory receptors, together with species-specific blocking of porcine ligands mediating human leukocyte interactions. Summary Cellular human innate immune responses are increasingly recognized as barriers to successful pig-to-human xenotransplantation, and only a detailed knowledge of the molecular mechanisms involved will allow us to overcome this barrier.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据